Masimo Corporation, established in 1989 and headquartered in Irvine, California, is a global leader in developing, manufacturing, and marketing non-invasive physiological monitoring technologies and hospital automation systems. A cornerstone of their offerings is the Masimo SET pulse oximetry, engineered to overcome the limitations of conventional oximeters by accurately measuring through patient motion and low perfusion. Their advanced Masimo rainbow SET platform further expands capabilities, providing non-invasive monitoring of various hemoglobin species, including oxygen saturation, pulse…
9 analysts rate MASI Buy on consensus.
Consensus price target: $178.60 (-0.75% downside from $179.95)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Sampath Anand EVP, Ops & Clinical Research | Jan 28, 2026 | Sale | 196 | $27.07K |
| Sampath Anand EVP, Ops & Clinical Research | Jan 28, 2026 | Sale | 6,560 | $900.16K |
| Sampath Anand EVP, Ops & Clinical Research | Jan 28, 2026 | Sale | 11,924 | $1.63M |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2026 | $1.53B | -27.1% | $-151.5M |
| 2024 | $2.09B | 0% | $-304.9M |
| 2024 | $2.09B | +2.26% | $-304.9M |
Stock data for MASI: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics